New hope for Tough-to-Treat hodgkin lymphoma: experimental drug shows promise
NCT ID NCT03580564
First seen May 07, 2026 · Last updated May 08, 2026 · Updated 1 time
Summary
This study tested an experimental drug called KL-A167 in 109 adults with classical Hodgkin lymphoma that had returned or stopped responding to prior treatments. The goal was to see how many patients had their tumors shrink or disappear. The drug works by helping the immune system attack cancer cells, and the results help doctors understand if this approach is safe and effective for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.